Inhibition of insulin‐like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival

Hepatocellular carcinoma (HCC) is the fifth most common primary cancer and second largest cause of cancer‐related death worldwide. The first‐line oral chemotherapeutic agent sorafenib only increases survival in patients with advanced HCC by less than 3 months. Most patients with advanced HCC have sh...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Hepatol Commun
Egile Nagusiak: Wang, Fang, Bank, Thomas, Malnassy, Gregory, Arteaga, Maribel, Shang, Na, Dalheim, Annika, Ding, Xianzhong, Cotler, Scott J., Denning, Mitchell F., Nishimura, Michael I., Breslin, Peter, Qiu, Wei
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2018
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5983153/
https://ncbi.nlm.nih.gov/pubmed/29881824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1181
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak